Aptevo wins $1.5 million Andy Hill CARE Fund grant for APVO451 IND-enabling work

Aptevo Therapeutics, Inc.

Aptevo Therapeutics, Inc.

APVO

0.00
  • Aptevo won a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund for APVO451.
  • Funding supports IND-enabling work for the nectin-4-targeted trispecific immunotherapy program in solid tumors.
  • Aptevo targets development candidate selection by year-end 2026, aiming to start IND-enabling studies in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606300805ACCESSWRNAPR_____1184427) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.